Page 49 - V7.2-2019-PR-GRANT

Grand Commandery officers from the Grand Commandery of California traveled to the
University of California, located in Berkeley to make a $65,000 check presentation to
Manoj Mohan Kulkarni, Ph.D. The Sir Knights presenting the check were: David Studley,
Grand Generalissimo and Trustee of the Knights Templar Eye Foundation; Howard Ramsey,
Past Grand Commander; Gregg Hall, Past Grand Commander; Brandon Duenas,
Past Commander, San Jose #10; Walter Crossley, Past Commander, San Jose #10

Inherited forms of retinal degenerations such as retinitis pigmentosa (RP) & Leber
Congenital Amaurosis (LCA) are a leading cause of blindness with a worldwide prevalence
of 1:3000-4000. RP and LCA are typically diagnosed early in childhood.

The affected pediatric population quickly loses the ability to see in dim light. This stage
is followed by loss of daylight vision resulting in complete blindness around adolescence.
Current treatments either slow vision loss or attempt to restore vision by making residual
neurons in the retina artificially light-sensitive. Recent studies in mouse models of RP
have demonstrated that such therapies are compromised by the appearance of abnormal
spontaneous neural activity, or “neural noise”, then can mask and thus degrade the important
visual signals. Identifying neural origins of this noise is a critical next step to finding ways to
reduce it and thus improve the efficacy of therapies.
Previous studies have demonstrated that a particular interneuron, the AII amacrine cell, may
generate and spread the abnormal activity to other neurons in the diseased retina. Dr. Kulkarni
hypothesizes that the neural circuits activating the AII amacrine cells become abnormal during
disease progression. These studies aim to identify the abnormal changes in the neural circuits,
and thus reveal potential pharmacological targets that may allow them to silence aberrant
activity while preserving the signals essential for vision. Knowledge from these studies is
expected to inform the development of therapies for treating affected children.

49